Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by A. Galvano
P2.04-10 Early Monitoring of Blood Biomarkers to Predict Nivolumab Efficacy in NSCLC Patients
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Related publications
P2.04-11 an IL-8/IFN-gammma/NLR Plasma Score to Predict Nivolumab Efficacy in Patients With NSCLC
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
P2.04-02 Predictive Value of Circulating Tumor Cells and Circulating Free DNA in NSCLC Patients Treated With Nivolumab
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
P2.04-12 a Genomic Signature [JAK2, JAK3, PIAS4, PTPN2, STAT3, IFNAR2] Predicts Baseline Resistance to Nivolumab in Advanced NSCLC.
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
182P: Intracranial Response to Nivolumab in NSCLC Patients With Untreated or Progressing CNS Metastases
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Nivolumab for NSCLC in Japanese Patients: Similar Benefits, but Beware of Pneumonitis
ESMO Open
Cancer Research
Oncology
P3.01-74 Clinical and Radiological Predictors of Efficacy to Nivolumab in NSCLC: A Multi-Institutional, Retrospective Cohort Study.
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
P2.04-19 Correlation of Clinicopathological Characteristics With Tumor Mutation Burden in Chinese Patients With NSCLC
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
OA11 First-Line Nivolumab + Ipilimumab in Asian Patients With Advanced NSCLC and High TMB (≥10 Mut/Mb): Results From CheckMate 227
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Emergence of Digital Biomarkers to Predict and Modify Treatment Efficacy: Machine Learning Study
BMJ Open
Medicine